Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease

Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimer’s Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the company’s investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimer’s disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Related Links:

David Porras, Esther Nistal, Susana Mart ínez-Flórez, Javier González-Gallego, María Victoria García-Mediavilla, Sonia Sánchez-Campos
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Lasse Gliemann, Nicolai Rytter, Peter Piil, Jannik Nilton, Thomas Lind, Michael Nyberg, Matthew Cocks, Ylva Hellsten
Source: Frontiers in Physiology - Category: Physiology Source Type: research
An-Hsuan Lin, Meng-Han Liu, Hsin-Kuo Ko, Diahn-Warng Perng, Tzong-Shyuan Lee, Yu Ru Kou
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Ascentia M. Seboko, M. M. Conradie, M. J. Kruger, William Frank Ferris, Magda Conradie, Mari van de Vyver
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Michael J. Zurawlew, Jessica A. Mee, Neil P. Walsh
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Pei-Ying S. Chan, Chia-Hsiung Cheng, Yu-Ting Wu, Changwei W. Wu, Ho-Ling A. Liu, Fu-Zen Shaw, Chia-Yih Liu, Paul W. Davenport
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Apolline Carrard, Elisa Fontana, Davide Malatesta
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Kristin Schink, Dejan Reljic, Hans J. Herrmann, Julia Meyer, Andreas Mackensen, Markus F. Neurath, Yurdag ül Zopf
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Qi-Lin Zhang, Guan-Ling Zhang, Ming-Long Yuan, Zhi-Xiang Dong, Hong-Wei Li, Jun Guo, Feng Wang, Xian-Yu Deng, Jun-Yuan Chen, Lian-Bing Lin
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Matthias Walter, Amanda H. X. Lee, Alex Kavanagh, Aaron A. Phillips, Andrei V. Krassioukov
Source: Frontiers in Physiology - Category: Physiology Source Type: research
More News: Merck | Pharmaceuticals | Study